2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vogt, L. Articles by de Zeeuw, D. Search for Related Content PubMed PubMed Citation Articles by Vogt, L. Articles by de Zeeuw, D.

Individual Titration for Maximal Blockade of the Renin-Angiotensin System in Proteinuric Patients: A Feasible Strategy?

Liffert Vogt^*, Gerjan Navis^*, and Dick de Zeeuw^*,

^* Division Nephrology, Department of Medicine; and Department of Clinical Pharmacology, Groningen University Medical Center, Groningen, the Netherlands

Address correspondence to: Dr. Liffert Vogt, Department of Internal Medicine, Division of Nephrology, Groningen University Medical Center, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. Phone: +31-50-361-2277; Fax: +31-50-361-9310; E-mail: l.vogt{at}int.azg.nl

Received for publication December 14, 2004. Accepted for publication December 15, 2004.

Agents that interfere with the renin-angiotensin system (RAS) reduce proteinuria and afford renal protection. The combination of different measures that serve maximization of RAS blockade is thought to improve the antiproteinuric efficacy. The feasibility and the efficacy of such a combination strategy were studied in nondiabetic patients with residual proteinuria during previous RAS blockade by individual antiproteinuric titration. Previous medication was replaced by irbesartan 300 mg combined with a diuretic. Lisinopril was added in increasing doses until a maximal dose of 40 mg/d. Titration stopped when target proteinuria (<1 g/d) was reached or further dose titration was not tolerated because of side effects. Residual proteinuria (median, 3.2 g/d; 95% confidence interval, 1.8 to 5.2 g/d) was significantly reduced with 55.6% (95% confidence interval, 16.0 to 73.2%; P < 0.02) on the maximal additional tolerated dose of lisinopril. The maximal dose of lisinopril was 10 mg in two of eight, 20 mg in two of eight, 30 mg in one of eight, and 40 mg in three of eight patients. At this dose, target proteinuria of <1 g/d was reached in two of eight patients. The number of patients with adverse events during dose titration was five of eight patients: two had cough; two had hyperkalemia (>5.5 mmol/L), one of whom had >50% increase of serum creatinine; and one had dizziness. In conclusion, individual titration for maximal RAS blockade, entailing dose titration of angiotensin-converting enzyme inhibitors on top of high-dose angiotensin II antagonists with diuretic, induces further reduction of residual proteinuria. However, this occurs at the expense of adverse events. To further improve renoprotective treatment strategies, it is important to explore other modes of antiproteinuric intervention in patients with residual proteinuria during RAS blockade.

This article has been cited by other articles:

				L. Vogt, D. de Zeeuw, A. J. J. Woittiez, and G. Navis Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients Nephrol. Dial. Transplant., November 26, 2008; (2008) gfn644v1. [Abstract] [Full Text] [PDF]

				C. Schindler ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist`s perspective after publication of the results of ONTARGET Therapeutic Advances in Cardiovascular Disease, August 1, 2008; 2(4): 233 - 248. [Abstract] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673